Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 40,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $47.62, for a total value of $1,904,800.00. Following the sale, the chief executive officer now owns 1,394,487 shares in the company, valued at approximately $66,405,470.94. The sale was disclosed in a filing with the SEC, which is available through this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, August 7th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00.
• On Friday, July 5th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.26, for a total value of $558,900.00.

Apogee Therapeutics Stock Down 2.1 %

Shares of NASDAQ:APGE opened at $47.25 on Friday. Apogee Therapeutics, Inc. has a twelve month low of $14.19 and a twelve month high of $72.29. The stock’s 50 day moving average is $45.80 and its 200-day moving average is $48.98. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -9.00 and a beta of 2.74.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). Equities research analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Driehaus Capital Management LLC raised its position in Apogee Therapeutics by 2.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after buying an additional 54,107 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Apogee Therapeutics by 2.2% in the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after purchasing an additional 45,241 shares during the period. Vanguard Group Inc. grew its holdings in Apogee Therapeutics by 60.7% during the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after purchasing an additional 705,795 shares during the period. Wellington Management Group LLP increased its position in Apogee Therapeutics by 0.3% in the fourth quarter. Wellington Management Group LLP now owns 1,591,478 shares of the company’s stock worth $44,358,000 after buying an additional 4,749 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Apogee Therapeutics by 51.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock valued at $77,770,000 after buying an additional 399,646 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on APGE. Bank of America assumed coverage on shares of Apogee Therapeutics in a research report on Friday, May 10th. They set a “buy” rating and a $80.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research note on Monday, May 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics presently has an average rating of “Buy” and a consensus price target of $78.50.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.